38.91
1.25 (3.32%)
| Penutupan Terdahulu | 37.66 |
| Buka | 37.41 |
| Jumlah Dagangan | 564,938 |
| Purata Dagangan (3B) | 732,490 |
| Modal Pasaran | 1,441,127,296 |
| Harga / Pendapatan (P/E Ke hadapan) | 38.76 |
| Harga / Jualan (P/S) | 6.08 |
| Harga / Buku (P/B) | 32.91 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Nov 2025 |
| Margin Keuntungan | -10.19% |
| Margin Operasi (TTM) | -23.48% |
| EPS Cair (TTM) | -0.610 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 38.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 410.02% |
| Nisbah Semasa (MRQ) | 0.910 |
| Aliran Tunai Operasi (OCF TTM) | 2.09 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -26.88 M |
| Pulangan Atas Aset (ROA TTM) | 0.90% |
| Pulangan Atas Ekuiti (ROE TTM) | -37.31% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Menaik | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Menaik | Bercampur | |
| Stok | Harrow, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 4.0 |
| Purata | 2.50 |
|
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company’s FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company’s ophthalmology-focused pharmaceutical compounding business. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 15.07% |
| % Dimiliki oleh Institusi | 57.11% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 74.00 (B. Riley Securities, 90.18%) | Beli |
| Median | 67.50 (73.48%) | |
| Rendah | 63.00 (BTIG, 61.91%) | Beli |
| Purata | 67.67 (73.91%) | |
| Jumlah | 6 Beli | |
| Harga Purata @ Panggilan | 45.15 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 12 Nov 2025 | 69.00 (77.33%) | Beli | 38.44 |
| 29 Sep 2025 | 64.00 (64.48%) | Beli | 48.40 | |
| Ladenburg Thalmann | 12 Nov 2025 | 66.00 (69.62%) | Beli | 38.44 |
| B. Riley Securities | 01 Oct 2025 | 74.00 (90.18%) | Beli | 48.37 |
| 23 Sep 2025 | 70.00 (79.90%) | Beli | 48.85 | |
| BTIG | 29 Sep 2025 | 63.00 (61.91%) | Beli | 48.40 |
| 24 Sep 2025 | 63.00 (61.91%) | Beli | 47.88 | |
| Lake Street | 29 Sep 2025 | 70.00 (79.90%) | Beli | 48.40 |
| Craig-Hallum | 23 Sep 2025 | 64.00 (64.48%) | Beli | 48.85 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 24 Nov 2025 | Pengumuman | Harrow to Present at Two Investor Conferences in December |
| 18 Nov 2025 | Pengumuman | Harrow Announces Closing of Acquisition of Melt Pharmaceuticals |
| 10 Nov 2025 | Pengumuman | Harrow Announces Third Quarter 2025 Financial Results |
| 27 Oct 2025 | Pengumuman | Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025 |
| 06 Oct 2025 | Pengumuman | ImprimisRx Announces Leadership Changes |
| 26 Sep 2025 | Pengumuman | Harrow to Acquire Melt Pharmaceuticals |
| 25 Sep 2025 | Pengumuman | Harrow Launches Harrow Access for All (HAFA) |
| 15 Sep 2025 | Pengumuman | Harrow Announces Agenda and Speakers for Investor & Analyst Day |
| 08 Sep 2025 | Pengumuman | Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030 |
| 08 Sep 2025 | Pengumuman | Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |